Predicting immunotherapy response in esophageal cancer
Part of Cancer, Digestive system clinical trials.
This study looks at a specific marker in lymph nodes to predict whether PD-1 immunotherapy (a type of cancer-fighting immune treatment) will work well before surgery in esophageal cancer patients. Understanding this marker may help doctors choose the best treatment plan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with esophageal squamous cell carcinoma (a specific type of esophageal cancer) confirmed by biopsy
- Able to have surgery and meet basic health standards (ECOG score 0–2, meaning you can perform daily activities with minimal limitation)
- Plan to receive neoadjuvant PD-1 immunotherapy (immune treatment given before surgery)
- No active autoimmune disease or history of certain autoimmune conditions
- No uncontrolled heart disease or active serious infections (HIV, hepatitis B or C, tuberculosis)
- No severe allergies to immunotherapy medications or protein-based treatments
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study examines specific immune cell patterns in lymph nodes to predict how well PD-1 immunotherapy (a type of cancer-fighting treatment) will work for advanced or recurrent esophageal cancer. The goal is to better understand which patients will benefit most from this treatment.
This study is for people with lung or esophageal cancer who will receive immunotherapy (drugs that help your immune system fight cancer). The researchers want to find markers in your blood and tumor that can predict how well the treatment will work.
This Phase 3 trial tests whether adding a PD-1 medicine (sintilimab) to standard chemo-radiation before surgery improves outcomes for locally advanced esophageal squamous cell cancer. It may help by strengthening the immune response while shrinking the tumor before an operation.
This study looks at patients with esophageal cancer who had a complete response to chemotherapy or radiation before surgery. It aims to understand how well these patients do over time, which could help guide future treatment decisions.
This study uses an “immune indicator model” to help predict how well a PD-1 antibody (a cancer-fighting immune drug) works when combined with chemotherapy for stage IV esophageal squamous cell cancer. If you qualify, you receive the treatment and the researchers also look for immune-related signs that may explain who benefits most.
This trial studies giving immunotherapy (anti–PD-1) together with chemotherapy before surgery for certain locally advanced esophageal squamous cell cancer. The goal is to improve how well the tumor responds before and after the operation.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.